Michiel G Betjes

List of Publications by Year in descending order

117 papers	5,107 citations	81900 39 h-index	102487 66 g-index
119 all docs	119 docs citations	119 times ranked	6230 citing authors

#	Article	IF	Citations
1	Activated CD4+ T Cells and Highly Differentiated Alloreactive CD4+ T Cells Distinguish Operationally Tolerant Liver Transplantation Recipients. Liver Transplantation, 2022, 28, 98-112.	2.4	8
2	Causes of Kidney Graft Failure in a Cohort of Recipients With a Very Long-Time Follow-Up After Transplantation. Frontiers in Medicine, 2022, 9, .	2.6	13
3	ARHGDIB and AT1R autoantibodies are differentially related to the development and presence of chronic antibody-mediated rejection and fibrosis in kidney allografts. Human Immunology, 2021, 82, 89-96.	2.4	10
4	Uremia-Associated Immunological Aging and Severity of COVID-19 Infection. Frontiers in Medicine, 2021, 8, 675573.	2.6	12
5	Expression of Senescence Marker TIGIT Identifies Polyfunctional Donor-Reactive CD4+ T Cells Preferentially Lost After Kidney Transplantation. Frontiers in Immunology, 2021, 12, 656846.	4.8	15
6	The FCGR3A 158ÂV/V-genotype is associated with decreased survival of renal allografts with chronic active antibody-mediated rejection. Scientific Reports, 2021, 11, 7903.	3.3	12
7	Is simplification of immunosuppressive medication a way to promote medication adherence of kidney transplant recipients? Findings from a randomized controlled trial. Transplant International, 2021, 34, 1703-1711.	1.6	4
8	Alemtuzumab as Second-Line Treatment for Late Antibody-Mediated Rejection of Transplanted Kidneys. Transplantation Proceedings, 2021, 53, 2206-2211.	0.6	8
9	Creating Options for Difficult-to-match Kidney Transplant Candidates. Transplantation, 2021, 105, 240-248.	1.0	6
10	T-Cell Epitopes Shared Between Immunizing HLA and Donor HLA Associate With Graft Failure After Kidney Transplantation. Frontiers in Immunology, 2021, 12, 784040.	4.8	8
11	Current Tolerance-Associated Peripheral Blood Gene Expression Profiles After Liver Transplantation Are Influenced by Immunosuppressive Drugs and Prior Cytomegalovirus Infection. Frontiers in Immunology, 2021, 12, 738837.	4.8	1
12	Validation of a Combined Transcriptome and T Cell Receptor Alpha/Beta (TRA/TRB) Repertoire Assay at the Single Cell Level for Paucicellular Samples. Frontiers in Immunology, 2020, 11, 1999.	4.8	3
13	COVIDâ€19 in solid organ transplant recipients: a singleâ€center experience. Transplant International, 2020, 33, 1099-1105.	1.6	71
14	High numbers of differentiated CD28null CD8+ T cells are associated with a lowered risk for late rejection and graft loss after kidney transplantation. PLoS ONE, 2020, 15, e0228096.	2.5	12
15	A very low thymus function identifies patients with substantial increased risk for long-term mortality after kidney transplantation. Immunity and Ageing, 2020, 17, 4.	4.2	15
16	Pretransplant Donor-Specific Anti-HLA Antibodies and the Risk for Rejection-Related Graft Failure of Kidney Allografts. Journal of Transplantation, 2020, 2020, 1-10.	0.5	18
17	Uremia-Associated Ageing of the Thymus and Adaptive Immune Responses. Toxins, 2020, 12, 224.	3.4	33
18	Title is missing!. , 2020, 15, e0228096.		0

#	Article	IF	Citations
19	Title is missing!. , 2020, 15, e0228096.		0
20	Title is missing!. , 2020, 15, e0228096.		0
21	Title is missing!. , 2020, 15, e0228096.		0
22	Title is missing!. , 2020, 15, e0228096.		0
23	Title is missing!. , 2020, 15, e0228096.		0
24	Banff lesions and renal allograft survival in chronic-active antibody mediated rejection. Transplant Immunology, 2019, 56, 101213.	1.2	11
25	Predictors of 90-Day Restart of Renal Replacement Therapy after Discontinuation of Continuous Renal Replacement Therapy, a Prospective Multicenter Study. Blood Purification, 2019, 48, 243-252.	1.8	7
26	The aftermath of acute kidney injury: a narrative review of long-term mortality and renal function. Critical Care, 2019, 23, 24.	5.8	88
27	Treatment with intravenous immunoglobulins and methylprednisolone may significantly decrease loss of renal function in chronic-active antibody-mediated rejection. BMC Nephrology, 2019, 20, 218.	1.8	23
28	Allocation to highly sensitized patients based on acceptable mismatches results in low rejection rates comparable to nonsensitized patients. American Journal of Transplantation, 2019, 19, 2926-2933.	4.7	32
29	Antibodies against ARHGDIB are associated with long-term kidney graft loss. American Journal of Transplantation, 2019, 19, 3335-3344.	4.7	46
30	Predictors of short-term successful discontinuation of continuous renal replacement therapy: results from a prospective multicentre study. BMC Nephrology, 2019, 20, 129.	1.8	32
31	Increased CD16 expression on NK cells is indicative of antibody-dependent cell-mediated cytotoxicity in chronic-active antibody-mediated rejection. Transplant Immunology, 2019, 54, 52-58.	1.2	22
32	Toward a Sensible Single-antigen Bead Cutoff Based on Kidney Graft Survival. Transplantation, 2019, 103, 789-797.	1.0	31
33	Effect of initial immunosuppression on long-term kidney transplant outcome in immunological low-risk patients. Nephrology Dialysis Transplantation, 2019, 34, 1417-1422.	0.7	7
34	Immune Cell Infiltrate in Chronic-Active Antibody-Mediated Rejection. Frontiers in Immunology, 2019, 10, 3106.	4.8	30
35	Chronic-active antibody-mediated rejection with or without donor-specific antibodies has similar histomorphology and clinical outcome - a retrospective study. Transplant International, 2018, 31, 900-908.	1.6	33
36	Immunomodulation By Therapeutic Mesenchymal Stromal Cells (MSC) Is Triggered Through Phagocytosis of MSC By Monocytic Cells. Stem Cells, 2018, 36, 602-615.	3.2	384

#	Article	IF	Citations
37	â€œWhat if this is my chance to save my life?â€•A semistructured interview study on the motives and experiences of end-stage renal disease patients who engaged in public solicitation of a living kidney donor. Transplant International, 2018, 31, 318-331.	1.6	7
38	Development and Validation of a Multiplex Non-HLA Antibody Assay for the Screening of Kidney Transplant Recipients. Frontiers in Immunology, 2018, 9, 3002.	4.8	25
39	A comprehensive characterization of aggravated aging-related changes in T lymphocytes and monocytes in end-stage renal disease: the iESRD study. Immunity and Ageing, 2018, 15, 27.	4.2	43
40	PIRCHE-II Is Related to Graft Failure after Kidney Transplantation. Frontiers in Immunology, 2018, 9, 321.	4.8	63
41	Tacrolimus intra-patient variability is not associated with chronic active antibody mediated rejection. PLoS ONE, 2018, 13, e0196552.	2.5	29
42	Differentially methylated regions in T cells identify kidney transplant patients at risk for de novo skin cancer. Clinical Epigenetics, 2018, 10, 81.	4.1	14
43	Renal function at 1Âyear after cardiac transplantation rather than acute kidney injury is highly associated with long-term patient survival and loss of renal function - a retrospective cohort study. Transplant International, 2017, 30, 788-798.	1.6	16
44	Significant Decreasing Incidence of Encapsulating Peritoneal Sclerosis in the Dutch Population of Peritoneal Dialysis Patients. Peritoneal Dialysis International, 2017, 37, 230-234.	2.3	28
45	pERK-dependent defective TCR-mediated activation of CD4+ T cells in end-stage renal disease patients. Immunity and Ageing, 2017, 14, 14.	4.2	12
46	Interferon-Gamma DNA Methylation Is Affected by Mycophenolic Acid but Not by Tacrolimus after T-Cell Activation. Frontiers in Immunology, 2017, 8, 822.	4.8	9
47	Inflammatory Conditions Dictate the Effect of Mesenchymal Stem or Stromal Cells on B Cell Function. Frontiers in Immunology, 2017, 8, 1042.	4.8	106
48	Protective Cytomegalovirus (CMV)-Specific T-Cell Immunity Is Frequent in Kidney Transplant Patients without Serum Anti-CMV Antibodies. Frontiers in Immunology, 2017, 8, 1137.	4.8	22
49	T-Cell Composition of the Lymph Node Is Associated with the Risk for Early Rejection after Renal Transplantation. Frontiers in Immunology, 2017, 8, 1416.	4.8	9
50	End-Stage Renal Disease Causes Skewing in the TCR VÎ²-Repertoire Primarily within CD8+ T Cell Subsets. Frontiers in Immunology, 2017, 8, 1826.	4.8	19
51	Variations in DNA methylation of interferon gamma and programmed death 1 in allograft rejection after kidney transplantation. Clinical Epigenetics, 2016, 8, 116.	4.1	22
52	Clinical consequences of circulating CD28-negative T cells for solid organ transplantation. Transplant International, 2016, 29, 274-284.	1.6	26
53	Loss of CD28 on Peripheral T Cells Decreases the Risk for Early Acute Rejection after Kidney Transplantation. PLoS ONE, 2016, 11, e0150826.	2.5	46
54	Vascular Multiplicity Should Not Be a Contra-Indication for Live Kidney Donation and Transplantation. PLoS ONE, 2016, 11, e0153460.	2.5	17

#	Article	IF	Citations
55	End stage renal disease patients have a skewed T cell receptor VÎ² repertoire. Immunity and Ageing, 2015, 12, 28.	4.2	20
56	Ureteral length in live donor kidney transplantation; Does size matter?. Transplant International, 2015, 28, 1326-1331.	1.6	6
57	Postâ€Transplantation Immunoadsorption Can Be Withheld in <scp>ABO</scp>â€Incompatible Kidney Transplant Recipients. Therapeutic Apheresis and Dialysis, 2015, 19, 513-517.	0.9	3
58	Long-Term Sequelae of Severe Acute Kidney Injury in the Critically Ill Patient without Comorbidity: A Retrospective Cohort Study. PLoS ONE, 2015, 10, e0121482.	2.5	11
59	Alternative Living Kidney Donation Programs Boost Genetically Unrelated Donation. Journal of Transplantation, 2015, 2015, 1-6.	0.5	4
60	Encapsulating peritoneal sclerosis is associated with T-cell activation. Nephrology Dialysis Transplantation, 2015, 30, 1568-1576.	0.7	13
61	Chronic Kidney Disease and Premature Ageing of the Adaptive Immune Response. Current Urology Reports, 2015, 16, 471.	2.2	48
62	Body mass index and outcome in renal transplant recipients: a systematic review and meta-analysis. BMC Medicine, 2015, 13, 111.	5.5	153
63	Allogeneic Mature Human Dendritic Cells Generate Superior Alloreactive Regulatory T Cells in the Presence of IL-15. Journal of Immunology, 2015, 194, 5282-5293.	0.8	12
64	A series of patients with minimal change nephropathy treated with rituximab during adolescence and adulthood. BMC Research Notes, 2015, 8, 266.	1.4	4
65	ABO-incompatible kidney transplant recipients have a higher bleeding risk after antigen-specific immunoadsorption. Transplant International, 2015, 28, 25-33.	1.6	38
66	CD4-Positive T Cells and M2 Macrophages Dominate the Peritoneal Infiltrate of Patients with Encapsulating Peritoneal Sclerosis. PLoS ONE, 2015, 10, e0120174.	2.5	15
67	Histological and Clinical Findings in Patients with Post-Transplantation and Classical Encapsulating Peritoneal Sclerosis: A European Multicenter Study. PLoS ONE, 2014, 9, e106511.	2.5	18
68	Patients with Encapsulating Peritoneal Sclerosis Have Increased Peritoneal Expression of Connective Tissue Growth Factor (CCN2), Transforming Growth Factor-Î²1, and Vascular Endothelial Growth Factor. PLoS ONE, 2014, 9, e112050.	2.5	33
69	Attitudes to Medication after Kidney Transplantation and Their Association with Medication Adherence and Graft Survival: A 2-Year Follow-Up Study. Journal of Transplantation, 2014, 2014, 1-9.	0.5	58
70	The First Fifty ABO Blood Group Incompatible Kidney Transplantations: The Rotterdam Experience. Journal of Transplantation, 2014, 2014, 1-6.	0.5	22
71	The impact of induction therapy on the homeostasis and function of regulatory T cells in kidney transplant patients. Nephrology Dialysis Transplantation, 2014, 29, 1587-1597.	0.7	45
72	Update on Controls for Isolation and Quantification Methodology of Extracellular Vesicles Derived from Adipose Tissue Mesenchymal Stem Cells. Frontiers in Immunology, 2014, 5, 525.	4.8	69

#	Article	IF	Citations
73	Rotterdam: Main port for organ transplantation research in the Netherlands. Transplant Immunology, 2014, 31, 200-206.	1.2	1
74	Uremia-associated immunological aging is stably imprinted in the T-cell system and not reversed by kidney transplantation. Transplant International, 2014, 27, 1272-1284.	1.6	55
75	Substantial Proliferation of Human Renal Tubular Epithelial Cellâ€“Reactive CD4+CD28null Memory T Cells, Which Is Resistant to Tacrolimus and Everolimus. Transplantation, 2014, 97, 47-55.	1.0	17
76	T-cell ageing in end-stage renal disease patients: Assessment and clinical relevance. World Journal of Nephrology, 2014, 3, 268.	2.0	30
77	Mesenchymal Stem Cells Induce an Inflammatory Response After Intravenous Infusion. Stem Cells and Development, 2013, 22, 2825-2835.	2.1	114
78	Immune cell dysfunction and inflammation in end-stage renal disease. Nature Reviews Nephrology, 2013, 9, 255-265.	9.6	405
79	Lower Mortality and Inflammation from Post-Transplantation Encapsulating Peritoneal Sclerosis Compared to the Classical Form. American Journal of Nephrology, 2013, 37, 223-230.	3.1	21
80	Novel biomarkers for the prediction of acute kidney injury in patients undergoing liver transplantation. Biomarkers in Medicine, 2013, 7, 947-957.	1.4	17
81	Loss of Renal Function Causes Premature Aging of the Immune System. Blood Purification, 2013, 36, 173-178.	1.8	61
82	Kinetics of Homeostatic Proliferation and Thymopoiesis after rATG Induction Therapy in Kidney Transplant Patients. Transplantation, 2013, 96, 904-913.	1.0	36
83	Circulating CD4+CD28null T Cells May Increase the Risk of an Atherosclerotic Vascular Event Shortly after Kidney Transplantation. Journal of Transplantation, 2013, 2013, 1-8.	0.5	15
84	Human Bone Marrow- and Adipose Tissue-derived Mesenchymal Stromal Cells are Immunosuppressive In vitro and in a Humanized Allograft Rejection Model. Journal of Stem Cell Research & Therapy, 2013, Suppl 6, 20780.	0.3	42
85	Human Allogeneic Bone Marrow and Adipose Tissue Derived Mesenchymal Stromal Cells Induce CD8+ Cytotoxic T Cell Reactivity. Journal of Stem Cell Research & Therapy, 2013, 3, 004.	0.3	19
86	Identification of Circulating Human Antigen-Reactive CD4+FOXP3+ Natural Regulatory T Cells. Journal of Immunology, 2012, 188, 1083-1090.	0.8	32
87	Terminally Differentiated CD8+ Temra Cells Are Associated With the Risk for Acute Kidney Allograft Rejection. Transplantation, 2012, 94, 63-69.	1.0	75
88	Uremia causes premature ageing of the T cell compartment in end-stage renal disease patients. Immunity and Ageing, 2012, 9, 19.	4.2	93
89	A killer on the road: circulating CD4+CD28null T cells as cardiovascular risk factor in ESRD patients. Journal of Nephrology, 2012, 25, 183-191.	2.0	40
90	Differential effects of age, cytomegalovirus-seropositivity and end-stage renal disease (ESRD) on circulating T lymphocyte subsets. Immunity and Ageing, 2011, 8, 2.	4.2	54

#	Article	IF	Citations
91	Premature aging of circulating T cells in patients with end-stage renal disease. Kidney International, 2011, 80, 208-217.	5.2	181
92	Risk Factors Associated with Encapsulating Peritoneal Sclerosis in Dutch Eps Study. Peritoneal Dialysis International, 2011, 31, 269-278.	2.3	82
93	Tamoxifen is associated with lower mortality of encapsulating peritoneal sclerosis: results of the Dutch Multicentre EPS Study. Nephrology Dialysis Transplantation, 2011, 26, 691-697.	0.7	88
94	Encapsulating peritoneal sclerosis: the state of affairs. Nature Reviews Nephrology, 2011, 7, 528-538.	9.6	90
95	Prevention of catheter-related bloodstream infection in patients on hemodialysis. Nature Reviews Nephrology, 2011, 7, 257-265.	9.6	60
96	Circulating pro-inflammatory CD4posCD28null T cells are independently associated with cardiovascular disease in ESRD patients. Nephrology Dialysis Transplantation, 2010, 25, 3640-3646.	0.7	55
97	CMV Seropositivity Determines Epoetin Dose and Hemoglobin Levels in Patients with CKD. Journal of the American Society of Nephrology: JASN, 2009, 20, 2661-2666.	6.1	26
98	Reversible Renal Failure Due to Bilateral Renal Sarcoma in a Patient with Acute Myeloid Leukemia. Renal Failure, 2009, 31, 606-609.	2.1	6
99	Resolution of IgM Nephropathy After Rituximab Treatment. American Journal of Kidney Diseases, 2009, 53, 1059-1062.	1.9	15
100	The human alloreactive CD4+ T-cell repertoire is biased to a Th17 response and the frequency is inversely related to the number of HLA class II mismatches. Blood, 2009, 114, 3947-3955.	1.4	33
101	Hepatitis B vaccine-specific CD4+ T cells can be detected and characterised at the single cell level: Limited usefulness of dendritic cells as signal enhancers. Journal of Immunological Methods, 2008, 330, 1-11.	1.4	31
102	IL-2 Producing Memory CD4+ T Lymphocytes Are Closely Associated with the Generation of IgG-Secreting Plasma Cells. Journal of Immunology, 2008, 181, 3665-3673.	0.8	50
103	Expansion of cytolytic CD4+CD28â^' T cells in end-stage renal disease. Kidney International, 2008, 74, 760-767.	5.2	95
104	Seropositivity for cytomegalovirus in patients with end-stage renal disease is strongly associated with atherosclerotic disease. Nephrology Dialysis Transplantation, 2007, 22, 3298-3303.	0.7	65
105	HYDROXYETHYLSTARCH SOLUTIONS VERSUS SALINE FOR THE TREATMENT OF INTRADIALYTIC HYPOTENSION. Journal of Renal Care, 2007, 33, 130-133.	1.2	0
106	Posttransplant Encapsulating Peritoneal Sclerosis: A Worrying New Trend?. Peritoneal Dialysis International, 2007, 27, 619-624.	2.3	95
107	Regional citrate versus heparin anticoagulation during venovenous hemofiltration in patients at low risk for bleeding: similar hemofilter survival but significantly less bleeding. Journal of Nephrology, 2007, 20, 602-8.	2.0	86
108	Progressive loss of renal function is associated with activation and depletion of naive T lymphocytes. Clinical Immunology, 2006, 118, 83-91.	3.2	126

#	Article	IF	Citations
109	The pathology of jaundice-related renal insufficiency: cholemic nephrosis revisited. Journal of Nephrology, 2006, 19, 229-33.	2.0	72
110	The effects of chronic kidney disease and renal replacement therapy on circulating dendritic cells. Nephrology Dialysis Transplantation, 2005, 20, 1868-1873.	0.7	49
111	Vitamin E-Coated Dialyzer Membranes Downregulate Expression of Monocyte Adhesion and Co-Stimulatory Molecules. Blood Purification, 2004, 22, 510-517.	1.8	12
112	Peripheral blood dendritic cells and GM-CSF as an adjuvantfor hepatitis B vaccination in hemodialysis patients. Kidney International, 2004, 66, 614-621.	5.2	70
113	Prevention of dialysis catheter-related sepsis with a citrate-taurolidine-containing lock solution. Nephrology Dialysis Transplantation, 2004, 19, 1546-1551.	0.7	201
114	Intraperitoneal Interleukin-8 and Neutrophil Influx in the Initial Phase of a Capd Peritonitis. Peritoneal Dialysis International, 1996, 16, 385-392.	2.3	28
115	Analysis of Inflammatory Mediators and Peritoneal Permeability to Macromolecules Shortly before the Onset of Overt Peritonitis in Patients Treated with CAPD. Peritoneal Dialysis International, 1995, 15, 134-141.	2.3	38
116	Immuno-effector characteristics of peritoneal cells during CAPD treatment: A longitudinal study. Kidney International, 1993, 43, 641-648.	5.2	64
117	Interleukin-8 Production by Human Peritoneal Mesothelial Cells in Response to Tumor Necrosis Factor-Â, Interleukin-1, and Medium Conditioned by Macrophages Cocultured with Staphylococcus epidermidis. Journal of Infectious Diseases, 1993, 168, 1202-1210.	4.0	128